AstraZeneca CEO Sir Pascal Soriot explains the reasoning behind its $50 billion expansion of operations across the U.S.

AstraZeneca plans to spend $50 billion to expand manufacturing and research capabilities in the U.S. by 2030, it said on ...

The U.K. biopharmaceutical giant’s plans include a proposal for a new drug substance manufacturing center focused on ...

The $50 billion target, which AstraZeneca plans to meet by 2030, includes new manufacturing projects in Virginia and ...

British biopharmaceutical giant AstraZeneca plans to invest $50 billion in the United States by 2030, expanding its presence ...

AstraZeneca Plc plans to invest $50 billion in the US before 2030, becoming the latest European pharma company to ratchet up ...

AstraZeneca ( AZN) said it is investing $50 billion in U.S. manufacturing by 2030, following the lead of big pharma peers ...

The company said the Virginia facility "would be AstraZeneca’s largest single manufacturing investment in the world." The ...

AstraZeneca (NASDAQ: AZN) has unveiled plans to invest $50 billion in U.S. manufacturing and RD infrastructure by 2030, ...

Virginia facility investment will be AstraZeneca’s largest yet. Maryland, Massachusetts, California, Indiana, Texas projects ...

Investment will fund drug manufacturing facility in Virginia and expand research and development and cell therapy ...

AstraZeneca announced that it will invest $50 billion in the U.S. by 2030, including a multi-billion-dollar manufacturing ...